Encision, Inc. Reports Third Quarter Fiscal Year 2017 Results; Sequential Quarterly Revenue Grows 4 Percent Post author:Sam Post published:February 7, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like BlueRock Therapeutics Expands Toronto Presence With R&D And Manufacturing Hub, Appoints Key R&D Leadership August 16, 2017 Study Compares Performance Of Masimo Acoustic Respiration Rate (RRa) And Nellcor Plethysmographic Respiration Rate In Volunteers July 30, 2017 Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phase II Data Demonstrating 11-Month Duration-Of-Action After A Single Dose In Patients With Glaucoma February 2, 2017
BlueRock Therapeutics Expands Toronto Presence With R&D And Manufacturing Hub, Appoints Key R&D Leadership August 16, 2017
Study Compares Performance Of Masimo Acoustic Respiration Rate (RRa) And Nellcor Plethysmographic Respiration Rate In Volunteers July 30, 2017
Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phase II Data Demonstrating 11-Month Duration-Of-Action After A Single Dose In Patients With Glaucoma February 2, 2017